11/27/2012

In a break from past practice, the FDA’s Office of Prescription Drug Promotion (OPDP) appears to be more closely scrutinizing drug companies’ public relations materials, as evidenced by two enforcement letters issued by OPDP last month citing a pitch letter and press releases. “Whether it’s a warning shot or a coincidence, it’s time for PR shops to brush up on the rules,” said Coalition for Healthcare Communication Executive Director John Kamp. Read more.

Full Story:
cohealthcom.org

Related Summaries